Benutzer: Gast  Login
Dokumenttyp:
journal article 
Autor(en):
Huebner, G; Link, H; Kohne, CH; Stahl, M; Kretzschmar, A; Steinbach, S; Folprecht, G; Bernhard, H; Al-Batran, SE; Schoffski, P; Burkart, C; Kullmann, F; Otremba, B; Menges, M; Hoffmann, M; Kaiser, U; Aldaoud, A; Jahn, A; German CUP Study Group 
Titel:
Paclitaxel and carboplatin vs gemcitabine and vinorelbine in patients with adeno- or undifferentiated carcinoma of unknown primary: a randomised prospective phase II trial. 
Abstract:
Platinum/taxane combinations are widely used in patients with carcinoma of unknown primary (CUP), yielding response rates of 30% and median overall survival of 9-11 months in selected patients. Yet these combinations have not been subject to a randomised trial to overcome selection bias, a major problem in CUP. We randomised 92 patients to either paclitaxel/carboplatin (arm A) or the non-platinum non-taxane regimen gemcitabine/vinorelbine (arm B). The primary endpoint was rate of practicability...    »
 
Zeitschriftentitel:
Br J Cancer 
Jahr:
2009 
Band / Volume:
100 
Heft / Issue:
Seitenangaben Beitrag:
44-9 
Sprache:
eng 
Print-ISSN:
0007-0920 
TUM Einrichtung:
III. Medizinische Klinik und Poliklinik